<DOC>
	<DOCNO>NCT00801151</DOCNO>
	<brief_summary>This multi-center , open-label non-randomized dose-escalation trial vorinostat give combination vinorelbine . Cohorts treat fix dose vinorelbine ( 25mg/m²/week continuously , represent schedule approve ) . Patients eligible enrolled standard 3+3 design start dose vorinostat 200 mg po qd 7/21 ( weekly schedule ) . Then , dose level explore . Toxicity schedule assess first cycle . Patients may receive 6 cycle study medication . Blood sample collect specified time point assess pharmacokinetic endpoint .</brief_summary>
	<brief_title>Vorinostat Combination With Vinorelbine Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must histologicallyconfirmed metastatic locally advanced cancer . Patient ≥ 18 year age day sign informed consent . Patient must performance status &lt; 1 ECOG performance scale . Patient must adequate organ function indicate follow laboratory value : Hematological : absolute neutrophil count ( ANC ) ≥ 1,5x109/L ; platelet ≥ 100 x109/L ; hemoglobin ≥ 9 g/dL Renal : calculated creatinine clearance b ≥ 60 mL/min Hepatic : serum total bilirubin ≤ 1.5 X ULN ; AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN ; alkaline phosphatase &gt; 2.5 X ULN , liver fraction ≤ 2.5 X ULN Coagulation : prothrombin time ( PT ) ≤1.2 X ULN ; partial thromboplastin time ( PTT ) ≤1.2 X ULN 1 . Patients adequate bone marrow function without current use colony stimulate factor 2 . Creatinine clearance calculate accord CockcroftGault formula For female patient childbearing potential : must negative serum pregnancy test within 72 h drug administration Male Female patient childbearing potential must agree use adequate method contraception throughout study start Visit 1 least 30 day last dose study medication . Patient voluntarily agree participate give write informed consent . Patient must available periodic blood sampling , study related assessment , management treat institution duration study . Patient currently participate participate study investigational compound device within 30 day sign informed consent . Patient pretreated one two investigational compound ( ie ; vinorelbine vorinostat ) Patients active CNS metastasis and/or carcinomatous meningitis uncontrolled brain metastasis exclude . However , patient CNS metastasis complete course therapy would eligible study provide clinically stable 3 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis ( 2 ) steroid stable dose steroid . Patient known hypersensitivity component study drug analog . Patient history current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study , best interest patient participate Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse . Patient pregnant nursing , Patient know Human Immunodeficiency Virus ( HIV ) positive . Patient known history Hepatitis B C. Patient history prior malignancy exception cervical intraepithelial neoplasia ; basal cell carcinoma skin ; adequately treat localized prostate carcinoma PSA &lt; 1.0 ; undergone potentially curative therapy evidence disease five year , deem low risk recurrence his/her treat physician Patient preexist grade 2 high neuropathy Patients receive radiotherapy 30 % bone marrow surface ( i.e whole pelvis ) Patients law protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>